Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dendritic cell depletion siRNA
- Development stage
- Discontinued
- Lead developer
- ToleroTech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intraperitoneal, Intradermal, Intranodal, Intraarticular, Intranasal
01
Overview
ToleroTech's dendritic cell depletion siRNA is a preclinical-stage therapeutic candidate developed for the prevention and treatment of acute graft-versus-host disease (GvHD). The program utilizes small interfering RNA (siRNA) technology to target and either deplete or modulate the function of dendritic cells, which are the primary antigen-presenting cells responsible for initiating the immune response in GvHD. By silencing key molecular pathways within these cells, the therapy aims to induce immune tolerance and mitigate the systemic inflammatory attack on host tissues following transplantation. The program was part of ToleroTech's broader platform for immune-associated diseases before the company became inactive.
- Other names
- Dendritic cell modulation siRNADendritic cell depletion / siRNA program
Beyond the preview
Go deeper on Dendritic cell depletion siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dendritic cell depletion siRNA.